CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma

By News Health
2 hours Ago

(MedPage Today) — Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high rate of non-relapse mortality in patients with multiple myeloma, according to a retrospective study…

Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/119503

Author :

Publish date : 2026-01-20 21:07:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Ixchiq Vaccine Pulled From U.S. Market Amid Safety Concerns

Parent-Led Intervention Started in NICU Boosted Executive Function at School Age

Study: Helping Lupus Patients With Money Issues Improves Their Health

After My Breast Cancer Diagnosis, My Practice Became a Lab for Change

Medicare Paying Billions More for Medicare Advantage vs Traditional Enrollees

Coming Radiotracer Shortage; Dedicated Cardiometabolic Training; New PFA Catheter